[GVHD].
Hirokawa
Makoto
M
Department of Internal Medicine III, Akita University School of Medicine.
Miura
Ikuo
I
Sawada
Ken-ichi
K
D000961:Antilymphocyte Serum / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D003937:Diagnosis, Differential; D004359:Drug Therapy, Combination; D006086:Graft vs Host Disease / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control / Q000628:therapy*; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use; D016853:Muromonab-CD3 / Q000627:therapeutic use; D017893:Photopheresis; D011239:Prednisolone / Q000008:administration & dosage; D011379:Prognosis; D016559:Tacrolimus / Q000627:therapeutic use
D000961:Antilymphocyte Serum; D016853:Muromonab-CD3; D016572:Cyclosporine; D011239:Prednisolone; D016559:Tacrolimus; D008727:Methotrexate